| Autor: |
McLay, Iain M., Halley, Frank, Souness, John E., McKenna, Jeffrey, Benning, Veronique, Birrell, Mark, Burton, Brenda, Belvisi, Maria, Collis, Alan, Constan, Alex, Foster, Martyn, Hele, David, Jayyosi, Zaid, Kelley, Mike, Maslen, Chris, Miller, Glen, Ouldelhkim, Marie-Claude, Page, Kenneth, Phipps, Simon, Pollock, Kenneth, Porter, Barry, Ratcliffe, Andrew J., Redford, Elisabeth J., Webber, Stephen, Slater, Bryan, Thybaud, Veronique, Wilsher, Nicola |
| Zdroj: |
Bioorganic & Medicinal Chemistry; February 2001, Vol. 9 Issue: 2 p537-554, 18p |
| Abstrakt: |
RPR132331, a 2-(2-dioxanyl)imidazole, was identified as an inhibitor of tumour necrosis factor (TNF)α release from lipopolysaccharide (LPS)-stimulated human monocytes. An intensive programme of work exploring the biology, toxicity and physical chemistry of a novel series of inhibitors, derived from RPR132331, has led to the identification of RPR200765A, a development candidate for the treatment of rheumatoid arthritis (RA). RPR200765A is a potent and selective inhibitor of p38 MAP kinase (IC50=50nM). It inhibits LPS-stimulated TNFα release both in vitro, from human monocytes (EC50=110nM), and in vivo in Balb/c mice (ED50=6mg/kg). At oral doses between 10 and 30mg/kg/day it reduces the incidence and progression in the rat streptococcal cell wall (SCW) arthritis model when administered in either prophylactic or therapeutic dosing regimens. The compound, which is a mesylate salt and exists as a stable monohydrate, shows good oral bioavailabiltiy (F=50% in the rat) and excellent chemical stability. The data from the SCW disease model suggests that RPR200765A could exhibit a profile of disease modifying activity in rheumatoid arthritis (RA) patients which is not observed with current drug therapies. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect